History
Alpers-Huttenlocher syndrome was first described in the 1930s without knowing the genetic background at that time 9 . The initial clinical description of MNGIE was reported in 1976 10 . Depletion of mtDNA in humans was first detected in 1991 in two infants with myopathy and liver disease without knowing the underlying mutation at that time 7 . The first nDNA mutation underlying MDS was found in the POLG1 gene and reported in 1999 by Naviaux et al 11 . In the same year the underlying molecular defect of MNGIE was defined by Nishino et al 12 . The first mutation in the DGUOK gene causing MDS was reported in 2001 by Mandel et al 13 . Thymidine-kinase-2-mutations were first detected as cause of MDS in 2001 by Saada et al 14 . SUCLA2-deficiency was first recognised as the cause of encephalo-myopathic MDS in infants by Elpeleg et al in 2005 15 . The first mutation in the MPV17 gene causing MDS was reported in 2006 by Spinazzola et al 16 . Encephalo-myopathic MDS due to SUCLG1-mutations was first described by Ostergaard et al in 2007 17 . MDS due to mutations in the RRM2B gene were first described in 2007 by Bourdon et al 18 . The first mutation in twinkle/PEO1 associated with MDS was reported in 2007 by Sarzi et al 19 .
Types of MDS

POLG1 deficiency a) Phenotype
POLG1-mutations causing MDS, present as syndromic or non-syndromic mitochondrial disorder. The most well-known of the syndromic MDS due to POLG1-mutations is AHS, manifesting as fatal brain and liver disease in children or young adults 20 . Alpers-Huttenlocher syndrome additionally presents with intractable seizures, neurodegeneration, and liver disease 9 .
Other AHS patients present with psychomotor regression, refractory seizures, stroke-like episodes, hepatopathy, or ataxia 21 or develop failure to thrive, feeding difficulties, various types of infantile epilepsy, psychomotor developmental delay, or muscle hypotonia 22 . In addition to POLG1-mutations, hepatopathy in MDS may be associated with mutations in the DGUOK, MPV17, SUCLG1, or PEO1 / twinkle gene 23 . Juvenile-onset AHS can begin with migraine-like headache and epilepsy and may lead to terminal status epilepticus and hepatic failure 24 . Movement disorder can be a rare clinical manifestation of AHS 25 . In some patients AHS additionally manifests as hypoglycemia, elevated lactate, moderate ketosis, and hepatic failure 26 , another syndromic MDS due to POLG1-mutations is MNGIE. Additionally, a number of non-syndromic phenotypes of POLG1-related MDSs have been described. An infant with MDS due to a POLG1-mutation presented with psychomotor retardation, hypotonia, and abnormal pain perception, resulting in debilitating biting of the thumb, lip, and tongue 27 .
b) Onset/outcome
Early-onset: Onset of MDS due to POLG1-mutations is usually in early infancy or childhood 28 . The outcome of AHS is usually fatal in early infancy.
Adult onset: Only some patients with MDS due to POLG1-mutations have been reported in whom the onset of the clinical manifestations was in adulthood 28 . In two patients aged 86 and 50 years (y) with late-onset chronic progressive external ophthalmoplegia (CPEO) and sensory neuropathy due to known POLG1-mutations, mtDNA studies in skeletal muscle showed evidence of multiple deletions and approximately 64% depletion of the mtDNA 29 . In a 58y female compound heterozygous POLG1-mutations resulted in multiple mtDNA deletions and depletion manifesting as multiple system atrophy 30 .
c) Genotype
Generally, POLG1-mutations (http://tools.niehs.nih.gov/ polg/) are associated with an extremely heterogeneous spectrum of phenotypes, ranging from adult-onset CPEO due to multiple mtDNA deletions, to rapidly fatal AHS due to mtDNA depletion (Table 1) 31 . POLG1-mutations leading to MDS include pointmutations and deletions 31 . POLG1-mutations causing AHS are most frequently present in a compound heterozygous form 32 . The most frequent POLG1-mutations causing AHS are the substitutions c.467A>T and c.2243G>C 20, 21, 33 . In addition to mtDNA depletion, AHS can be also due to multiple mtDNA deletions (Table 1) 21 .
d) Instrumental findings
Muscle biopsy shows myopathic changes with cytochrome-coxidase (COX)-deficiency 21 . COX-deficiency is uniform and characteristic for severe complex IV deficiency, as in AHS or mitochondrial disorder due to SCO2-mutations. Contrary to uniform COX-deficiency in children, adults or adolescents show complete absence of COX activity exclusively in single fibers (COX-ve fibers). Histological examination of the muscle biopsy can be normal but biochemical investigation may reveal multiple defects of respiratory chain complexes (RCCs), in particular RCCII+RCCIII, and RCCIV 27 . POLG1-mutations often do not alter complex II since complex II contains no mtDNA encoded sub-units 27 . Cerebral imaging can be normal or reveal hypoplasia of the corpus callosum, disturbed myelination of the temporo-occipital area, or hydrocephalus 27 . Neuropathologic investigations reveal lesions in the right striatal area and the inferior colliculi, typical for Leigh syndrome 26 . The biochemical profile most suggestive of a MDS is multiple respiratory chain deficiencies with relative sparing of complex II.
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DGUOK-deficiency a) Phenotype
Phenotypically, DGUOK-mutations manifest in two forms, as hepato-cerebral MDS with a neonatal onset 34 or as isolated hepatopathy 35, 36 . Patients with the hepato-cerebral form present with failure to thrive, microcephaly, rotatory nystagmus, muscle hypotonia, hepato-splenomegaly, jaundice, or ascites 37 . With progression of the disease patients develop cholestatic liver failure with hypoalbuminemia, portal hypertension, intractable ascites, hypersplenism with thrombocytopenia, and severe coagulopathy 35, 37 . A rare complication of DGUOK-deficiency is hepato-cellular carcinoma 38 . Patients with isolated liver disease may additionally develop renal insufficiency 36 .
b) Onset/outcome
Early-onset: Onset is neonatal 35, 37 or in early infancy 34 . Babies affected by the hepato-cerebral form usually die within a few months after birth 37 . Patients affected by the isolated hepatic form have an infantile or juvenile onset 35 and survive into adolescence 39 .
Adult onset: No patients with adult onset of the disease have been reported so far.
c) Genotype
Deoxyguanosine-kinase-deficiency is transmitted in an autosomal recessive manner 36 . Deoxyguanosine-kinase is one of the two mitochondrial deoxynucleoside salvage pathway enzymes involved in precursor synthesis for mtDNA replication 39 . Deoxyguanosine-kinase catalyses the phosphorylation of purine deoxy-ribonucleosides, the first step of the mitochondrial deoxypurine salvage pathway 40 . One of the pointmutations in the DGUOK gene causing MDS is the transition c.313C>T in exon 3, resulting in a stop codon 37 . Other mutations are the transitions c.34C>T 40 and c.3G>A, the transversion c.494A>T, the insertion c.766_767insGATT 41 , and the splice site insertion c.444-62C>A 42 . Mutations which cause isolated liver disease include the transition c.137A>G and the transversion c.797T>G 39 . Deoxyguanosine-kinase-deficiency-mutations not only cause MDS but also multiple mtDNA deletions, manifesting as mitochondrial myopathy with or without CPEO, recurrent rhabdomyolysis, hepatopathy, lower motor neuron disease, or mild cognitive impairment (Table 1) 43 . In some cases DGUOKmutations resulted from maternal uniparental disomy 2 44 .
d) Instrumental findings
Blood testing shows lactacidosis, hyperbilirubinemia, elevated liver transaminases, coagulopathy, elevated ferritin, α-fetoprotein, severe preprandial hypoketotic hypoglycemia, hypoalbuminemia, and elevated alanine and tyrosine 35, 37, 41 . Urinary organic profile shows mild elevation of dicarboxylic acids 37 . Cerebral imaging is usually normal in DGUOKdeficiency but some patients show moderate hyperintensity of the globus pallidus bilaterally and subtentorial abnormal myelination 42 . Liver biopsy shows bile ductular proliferation, cholestasis, micro-vesicular steatosis, and bridging fibrosis leading to micronodular transformation or cirrhosis 35, 37, 41 . Histological work-up of the pancreas shows islet cell hyperplasia resulting in hyperinsulinism and severe hypoglycemia 41 . In mtDNA depleted tissues iron overload can be found 41 .
TK2 deficiency a) Phenotype
Thymidine kinasekinase (TK2)-mutations manifest clinically as myopathic form of MDS 45 , more rarely as encephalomyopathy [46] [47] [48] , or very rarely as hepato-myopathic form 49 . Patients with the myopathic form present with generalized muscle weakness predominantly of axial and proximal muscles but also affecting facial, ocular, and respiratory muscles 50 . Some of these patients develop normally until 12-14 months-of-age to become symptomatic thereafter 51 . Pediatric patients with the encephalo-myopathic form have a normal early developmental phase, followed by psychomotor regression, seizures, or myopathy 52 . In some infants, MDS manifests with periventricular pseudocysts 53 . Some patients develop severe hypoacusis 54 . Rarely, TK2-mutations initially present phenotypically as spinal muscular atrophy 52, 55 . Patients with adult-onset MDS due to TK2-mutations present with slowly progressive myopathy 50 .
b) Onset/outcome
Early-onset: The myopathic form presents as an early-onset or adult-onset disease 50 . Patients with the early-onset form usually die within a few months after birth 49, 55, 56 or survive the first or second decade of life 55, 57 . Patients with the encephalomyopathic phenotype die within a few months or years after birth 47, 48 .
Adult-onset: Patients with adult-onset MDS due to TK2-mutations present with slowly progressive myopathy 50 , manifesting as generalised muscle weakness of the axial and proximal limb muscles. Facial, ocular, and respiratory muscle weakness was also reported in three other adult patients 58 . TK2-mutations also cause arCPEO with multiple mtDNA deletions (Table 1) 59 . Patients with the adult-onset form have normal life expectancy 53 .
c) Genotype
TK2 mutations are present in the compound heterozygous form 56 or in the homozygous form 47 . TK2-mutations result in reduction of the mtDNA content down to <10% of normal 60 . Some TK2-mutations do not cause mtDNA depletion 61 . TK2-mutations not only cause MDS but also multiple mtDNA deletions, manifesting as arCPEO in adults (Table 1) 58 .
d) Instrumental findings
Muscle biopsy shows typical features of mitochondrial myopathy with a mosaic pattern of COX-negative and raggedred fibers 50 . Biochemical investigations reveal multiple RCC deficiencies 50 or normal activity of RCCs 57 . In accordance with the disease's relatively slow progression, the residual mtDNA content is higher in adult cases than that observed in pediatric cases. This difference could not be explained by the type of TK2-mutations or by the residual TK2 activity 50 . The minimal amount of mtDNA density in single muscle fibers to allow residual COX activity was determined as 0.01 mtDNA/μm 3, 62 .
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MPV17-deficiency a) Phenotype
Mitochondrial inner membrane protein (MPV17)-mutations are responsible for a hepato-cerebral form of MDS 6 . The phenotype is characterised by recurrent episodes of severe hypoglycemia, hepatopathy evolving towards cirrhosis and liver failure, and growth retardation 6 . Patients present with poor feeding, failure to thrive, diarrhoea, and recurrent vomiting 6 . Within the first few months of life they develop generalised muscle wasting and muscle hypotonia 6 . Common neurological phenotypic features include microcephaly, ataxia, developmental delay, muscle weakness, seizures, ischemic stroke, or dystonia [63] [64] [65] [66] . Patients who survive develop polyneuropathy and lesions of the cerebellum and the cerebral cortex 6 . The phenotype follows a two-stage presentation with metabolic dysfunction progressing to hepatic failure as the first stage and neurological involvement as the second stage 64 .
b) Onset/outcome
Earl onset: Onset is usually at birth or early infancy 6 . The outcome is generally poor and patients die within a few weeks or months after birth 6, 67 . Exceptionally, some patients survive into their late teens 63, 68 .
c) Genotype
Mitochondrial inner membrane protein (MPV17) encodes a small protein of unknown function located on the inner mitochondrial membrane 6 . To date 20 mutations in 29 patients have been described 6, 69 . Homozygous, heterozygous or compound heterozygous nonsense or missense mutations or macrodeletions have been reported 64 . Mutations in the MPV17 gene additionally result in multiple mtDNA deletions but normal mtDNA content (Table 1) 70 . Mitochondrial inner membrane protein mutations are also responsible for Navajo neurohepatopathy 69 , which is a hepato-cerebral variant of MDS, presenting with hepatopathy, polyneuropathy, corneal anesthesia and scarring, acral mutilation, leukoencephalopathy, failure to thrive, and recurrent metabolic acidosis with intercurrent infections 68 .
d) Instrumental findings
Blood chemical investigations show elevated liver transaminases, hyperbilirubinemia, hypoalbuminemia, and coagulopathy 6 . Additionally, plasma amino acids, urine amino acids, and serum lactate may be elevated. Abdominal imaging shows hepatomegaly and nephrolithiasis 6 . Cerebral magnetic resonance imaging (MRI) shows cortical and subcortical hyperintensities involving the cerebellar white matter and the hili of the dentate nuclei 6 . Other patients show hyperintensities in the reticular formation of the lower brain stem and within the reticulospinal tracts 71 . Aminoaciduria in MPV17-mutations is attributed to proximal tubulopathy 69 .
TYMP deficiency a) Phenotype
Thymidine phosphorylase-mutations manifest clinically as MNGIE, which is clinically characterised by ptosis, ophthalmoparesis, gastro-intestinal dysmotility, cachexia, neuropathy, myopathy, and leucencephalopathy 70, 72 . Gastrointestinal manifestations include diarrhoea, abdominal pain, nausea or vomiting, abdominal cramps, weight loss, borborygmi, failure to thrive, intestinal pseudoobstruction, bloating, or intestinal invagination 70 why most patients develop severe intestinal pseudo-obstruction 73 . Ocular manifestations include ptosis, ophthalmoparesis, eye wandering, or loss of vision 70 . CNS manifestations include leucencephalopathy, but it remains asymptomatic in 80% of the cases. In the remaining patients it manifests as cognitive impairment, dementia, seizures, or headache 70 . Peripheral nervous system (PNS) manifestations include demyelinating polyneuropathy and myopathy, the latter in about one quarter of the patients. Initial manifestations other than gastrointestinal and ocular include neuropathy, hypoacusis, dry mouth, tinnitus, or myopathy and exercise intolerance 70 . Initial manifestations are often polyneuropathy or CPEO. An additional manifestation is endocrine or exocrine pancreas insufficiency, diverticulosis, hypertriglyceridemia, short stature, cardiomyopathy, or course bronze skin 70 . Most patients present with the complete manifestations of the syndrome and only some with incomplete expression of the phenotype 73 . In the early stages MNGIE can be misdiagnosed as hereditary neuropathy, eating disorder, coeliac disease, inflammatory bowel disease, or Whipple disease 70 .
b) Onset/outcome
Early onset: Onset is typically before age 30y (mean: 18y) 70 . However, the majority of patients report their first symptoms before age 12y 70 . An early-onset and adult-onset MNGIE type are differentiated 74, 75 . Though there are indications that allogeneic hematopoetic stem cell transplantation is beneficial in at least some MNGIE patients, it is still associated with a high mortality 70 . Early onset does not correlate with short life expectancy 70 .
Adult onset: Patients with adult-onset MNGIE present with similar manifestations as patients with the early-onset form. Contrary to patients with early-onset MNGIE, patients with lateonset MNGIE can develop rapidly progressive disease 70 . Mean age at death in these patients is 35y 70 . The later the onset of adult MNGIE the longer the patients survive 76 .
c) Genotype
Among TyMP-mutations causing MNGIE, point-mutations are the most common type of splice-site mutations 70 . To date, over 30 different mutations have been reported 77 . TyMPmutations are transmitted via an autosomal-recessive trait of inheritance and not only cause MDS but also multiple mtDNA deletions (Table 1) 73 . TyMP-mutations result in complete abolition or severe reduction of the TyMP activity 73 .
d) Instrumental findings
Rapid tests to diagnose MNGIE include determination of the TyMP activity, which is decreased in MNGIE patients, and determination of the thymidine levels, which are increased in MNGIE 73 . In the early-onset form, TyMP-mutations cause thymine phosphorylase activity reduction to <10% of normal 74 . In late-onset MNGIE the activity of the thymine phosphorylase is 10-15% 70 . CSF protein can be slightly elevated 70 . White matter lesions in MNGIE are patchy initially, eventually becoming diffuse or confluent 70 . In some patients severe hypokalemia occurs 70 . Some patients present with lactacidosis 70 . Nerve conduction studies reveal demyelinating polyneuropathy in most patients. Muscle biopsy shows COX-negative fibers and, more rarely, ragged-red fibers. Biochemical investigations reveal deficient RCCIV, RCCI and RCCIV, or RCCI+III+IV activities 70 . However, MNGIE patients without involvement of skeletal muscle have been also reported 78 .
SUCLA2-deficiency a) Phenotype
SUCLA2-related MDS is a rare disorder of infancy clinically characterised by neonatal or infantile-onset severe muscle weakness, muscle hypotonia, muscle wasting, resulting in failure to achieve independent ambulation, progressive kypho-scoliosis, dystonia, hyperkinesia with athetoid or choreiform movements, epilepsy (infantile spasms, generalised convulsions), growth retardation, or severe hypoacusis 79, 80 . This compilation of manifestations represents the Leigh-like phenotype.
b) Onset/outcome
Early onset: Onset of clinical manifestations is at birth or within the first few months thereafter 4, 80 . The outcome is poor with early lethality 80 .
c) Genotype
SUCLA2 deficiency is due to mutations in the SUCLA2 gene encoding the ADP-binding specific β-subunit of the tricarbonic acid (TCA)-cycle enzyme succinyl-CoA synthetase. SUCLA2 is related to SUCLA1 in that SUCLA1 encodes the catalytic α-subunit of the TCA-cycle enzyme succinyl-CoA synthetase. Mutations in the SUCLA2 gene reported to cause MDS include the point mutations c.352G>A, c.850C>T, c.534+1G>A 79 , and c.308C>A 81 . SUCLA2-associated MDS is most prevalent on the Faroe islands with a mutant allele frequency of 2% 79 .
d) Instrumental findings
Methyl-malonic acid is mildly or moderately elevated in the urine of these patients 81 . Methyl-malonic acid can be also elevated in the serum. Compared to methylmalonic aciduria due to mutations in the methylmalonic mutase, elevation of methylmalonic acid in SUCLA2 deficiency is mild to moderate. There may be lactacidosis and increased C3-carnitine or C4-dicarboxylic-carnitine 80 . Urinary excretion of C4-dicarboxyliccarnitine is markedly elevated 80 . Cerebral imaging shows diffuse atrophy, lesions in the putamen and caudate nuclei, or delayed myelination, similar to findings in Leigh syndrome 79, 80 .
SUCLG1-deficiency a) Phenotype
SUCLG1-deficiency is clinically characterised by intrauterine growth retardation (dysmaturity), hepatomegaly, muscle hypotonia, respiratory insufficiency due to acidosis, and severe hypothermia 17 . Respiratory insufficiency is usually so severe that patients require ventilatory support 17 .
b) Onset/outcome
Early onset: Onset is congenital 17 and the outcome poor with death within a few days after birth 4, 17 . Occasionally, patients survive into adolescence 82 .
c) Genotype
SUCLG1 encodes the alpha-subunit of the succinate-CoA ligase 83 . Deletions and missense mutations causing MDS have been reported [82] [83] [84] [85] [86] .
d) Instrumental findings
There is severe neonatal lactacidosis but also elevation of pyruvate 17 . Some patients develop hypoglycemia 17 . Urine screening shows elevated levels of lactate and pyruvate, mildly or moderately elevated excretion of methyl-malonate and methylcitrate, and slightly elevated excretion of the Krebs cycle intermediates fumarate, malate, citrate, and 2-oxoglutarate 17 . Plasma and urine amino acid determination reveals highly elevated taurine and glycine and moderately elevated lysine and alanine 17 . Electroencephalography (EEG) can show focal paroxysmal activity, sharp waves, and triphasic potentials bilaterally 17 . Post-mortem morphology of the skeletal muscle shows intracellular lipid accumulation exclusively 17 . Liver histology shows microvesicular steatosis and sinusoidal dilatation 17 . Activity of RCCI+III+IV can be decreased in muscle and liver 17, 83, 86 .
RRM2B deficiency a) Phenotype
Clinical manifestations start at birth or shortly afterwards and include failure to thrive, congenital deafness, muscle weakness, axial hypotonia, diarrhoea, proximal tubulopathy, seizures, lactacidosis, respiratory distress, and intractable status epilepticus 18, 21 . In a single adult patient RRM2B-mutations manifested as MNGIE-phenotype 87 .
b) Onset/outcome
Early onset: Onset of clinical manifestations is congenital or shortly after birth with rapidly progressive course and death within a few weeks or months later 18, 21 . Less severe phenotypes have been also reported in some patients who survived until age three years 88 .
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Adult onset: A single patient with onset at age 30y who developed a MNGIE phenotype due to a RRM2B-mutation has been reported 87 . Typical findings indicating adult onset RRM2B deficiency include bulbar dysfunction, hearing loss, and gastrointestinal dysfunction (gastrointestinal dysmotility, borborygmi, early satiety, diarrhea, constipation, vomiting, weight loss) 89 .
c) Genotype
The phenotype is caused by nonsense, missense, splice-site, or in-frame deletions in the RRM2B gene 18 . These mutations lead to mtDNA depletion to 1% of the normal content 18 . RRM2B-mutations not only cause mtDNA depletion but also multiple mtDNA deletions, resulting in a KSS-phenotype (Table  1) 90 .
d) Instrumental findings
Blood chemical investigations show mild to severe lactacidosis 18 . Lactate can be also elevated in the cerebrospinal fluid (CSF) 91 . Histological investigations of the muscle biopsy shows COX-negative fibers and ragged-red muscle fibers 18 . Biochemical investigations of the muscle homogenate reveal decreased malate and glutamate oxidation, isolated RCCIV deficiency, combined RCCI+III+IV deficiency 18 , or combined RCCI+III+IV+V deficiency 92 . Magnetic resonance imaging of the cerebrum shows mild hypomyelination 92 . Electroencephalogram shows generally increased slow wave activity 91 . In addition to mtDNA depletion, RRM2B-mutations also cause multiple mtDNA deletions in adults (Table 1) 90 . Urinary organic acids show combined keto-acidosis and lactic acidosis 91 .
PEO1 / Twinkle deficiency a) Phenotype
Mitochondrial depletion syndromes due to twinkle-mutations manifest as encephalopathy, hepato-encephalopathy, or CPEO. In the first description of a twinkle-mutation causing mtDNA depletion, two siblings with the hepato-cerebral form of MDS were presented 93 . The phenotype was characterised by severe, early-onset encephalopathy, liver involvement, hypotonia, athetosis, ophthalmoparesis, hearing impairment, sensory neuropathy, intractable epilepsy, and ataxia 94 . In adults, the most common manifestation of MDS due to twinkle-mutations is adCPEO, characterised by isolated affection of external eye muscles 94 . Twinkle deficiency also manifests as infantile-onset spinocerebellar ataxia (IOSCA) or as mitochondrial recessive ataxia syndrome (MIRAS) 5 , why IOSCA and MIRAS should be regarded as subtypes of MDS 5 . More rare manifestations in IOSCA include refractory status epilepticus, epilepsia partialis continua, migraine-like headache, and psychiatric abnormalities 95 . The initial status epilepticus occurs between 15 and 34y of age 95 .
b) Onset/outcome
Early onset: Twinkle-mutations usually cause early-onset MDS 94 .
Adult onset: Rarely, adult-onset MDS due to twinklemutations has been reported 8 . The most common adult-onset manifestation of twinkle-mutations is adCPEO 94 . Other initial manifestations of adult-onset MDS due to twinkle-mutations are epilepsy, migraine-like headache, and psychiatric abnormalities 94 .
c) Genotype
Mutations in the twinkle gene most frequently cause multiple mtDNA deletions (Table 1) 93,96 . Recently, however, it has been shown that certain twinkle-mutations also cause mtDNA depletion, clinically manifesting as encephalopathy or hepatoencephalopathy 93, 95 . These phenotypes resemble those of POLG1-mutations causing MDS (AHS) 95 . Accordingly, mtDNA depletion is most prevalent in liver and only mild in the skeletal muscle 94 . Twinkle-mutations causing mtDNA depletion occur in the homozygous or compound heterozygous form 95 .
d) Instrumental findings
Serum transaminases can be elevated 94 . Cerebral MRI shows focal stroke-like lesions, which vary between small cortical lesions to large hemispheric edematous lesions 95 . Neuropathological investigations show laminar cortical necrosis or hippocampal damage 95 .
Other causes of mtDNA depletion
In addition to MDS due to mutations in any of the nine genes, mtDNA depletion experimentally also occurs if OPA1 variants are silenced 81, 96 . A further candidate gene that could be responsible for MDS is GFER 81 or DNA2. The mtDNA content can be reduced in HIV patients under nucleoside reverse transcriptase inhibitors (NRTIs) 97 . Highly active anti-retroviral therapy (HAART) leads to mtDNA depletion and lipoatrophy through direct interference with POLG1. Additionally, HAART causes oxidative stress by increasing reactive oxidative species (ROS) production, which is buffered by the antioxidative capacity of mitochondria and up-regulation of the mitochondrial protease LON 98 . HIV patients on HAART and lipatrophy have mtDNA depletion in fat 99 .
MDS in adults
In the majority of the cases, MDS is a condition of early infancy or juvenile age and has a poor prognosis. The reason why MDS is highly prevalent in the early ages is unclear. One reason could be that due to the poor prognosis in most of the MDSs, affected patients do not survive into adulthood. Mutated genes associated with early-onset MDS include POLG1, DGUOK, TK2, MPV17, TyMP, SUCLA2, SUCLG1, RRM2B, and PEO1 / twinkle, A typical infantile-onset MDS is IOSCA 5 . Thus, all genes involved in MDS present with the early-onset form but some of them (POLG1, TK2, TyMP, RRM2B, and PEO1 also present with adult-onset subtypes. Conditions, which represent adult-onset MDS include AHS due to POLG1-mutations occurring in young adults 20 , adult-onset MDS due to TK2-mutations presenting with slowly progressive myopathy 50 and normal life expectancy 54 , adult-onset MNGIE due to TyMPmutations 74, 100 , adult-onset MDS due to RRM2B-mutations, and adult-onset MDS due to PEO11 twinkle-mutations 8, 101 . Why some of the MDSs survive into adulthood or have their onset in adulthood, is unknown. It can be speculated, however, that some THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES MDSs result in biochemical defects which are compatible with survival into adulthood or that the amount of mtDNA depletion has a progressive course and manifests clinically not before a certain cut-off is undercut. The phenotype of adult-onset MDS can vary greatly from that in early-onset MDS. While MDS due to POLG1 mutations frequently manifests as severe multisystem disease, MDS due to POLG1 mutations in adults presents as CPEO and sensory neuropathy 29 or as multiple system atrophy 30 . Patients with very late-onset MNGIE may present without neuropathy 75 . Adult patients carrying RRM2B mutations present with ophthalmoplegia, ptosis, gastrointestinal dysmotility, cachexia, peripheral neuropathy, and brain magnetic resonance imaging changes 87 . Overall, among MDS with adult onset, the clinical presentation may vary compared to early onset MDS but final conclusions on this matter can be drawn only after further studies on larger cohorts.
Diagnosis
The diagnosis of MDS is based on the clinical presentation, blood chemical investigations, instrumental investigations, verification of the mtDNA depletion in muscle, liver, or cerebrum, and detection of the mutation underlying the mtDNA depletion. Differential diagnoses that have to be excluded are hemochromatosis in the hepatic form or hepato-cerebral form of MDS 35 .
Techniques to detect mtDNA depletion
The most frequently applied technique to reveal mtDNA depletion is quantitative (real-time) polymerase chain reaction (PCR) 3, 27, 56 . mtDNA depletion is said to be best detected in tissues such as muscle, brain, or liver, but not in blood or skin fibroblasts 3 . This is why those tissues, which are predominantly affected, should be biopsied (Table 2) . Comparative genomic hybridization (CGH) or high-density single-nucleotide polymorphism (SNP) array analysis are only rarely applied and may reveal MDS due to uniparental isodisomy 102 .
Treatment a) Non-invasive
There is no treatment available for MDS. Only symptomatic measures can be recommended in case of epilepsy, cognitive impairment, movement disorder, migraine-like headache, strokelike episode, myopathy, failure to thrive, or liver disease 103 . In patients with myopathy or encephalo-myopathy, physical therapy could be beneficial to promote mobility and prevent contractures. Mechanical assistance with a wheelchair will guarantee mobility, bracing may delay kyphoscoliosis 80 . Muscle relaxants can be beneficial in case of dystonia or hyperkinesia 80 . Antiepileptic drugs are essential to treat concomitant epilepsy. Patients with cholestasis profit from formulas with enriched medium-chain-triglyceride content and fractional meals with enteral nutrition at night 36 . Severe hypoglycemic episodes in MPV17-deficiency can be prevented by corn-starch-based meals 6 . Regular glucose intake at short intervals can also slow progression of liver dysfunction in MPV17-associated MDS 63 . In patients with liver involvement, drugs with liver toxicity, such as valproate, isoniazid, acetaminophen, and others should be absolutely avoided 36 . Promising results with dAMP / dGMP supplementation have been reported in myotubes carrying TyMP-mutations, DGUOK-mutations, or POLG1-mutations 103 .
In vitro supplementation with dAMP / dGMP resulted in a significant increase in the mtDNA copy number in myotubes from patients with DGUOK-mutations 103 . In POLG1-mutations the improvement of mtDNA depletion is mild and nonsignificant 103 . Patients with liver failure, ascites, and coagulopathy require regular transfusions of fresh frozen plasma, vitamin K, ursadeoxycholic acid, and spironolactone 37 .
b) Invasive
Intermittent positive pressure ventilation may be necessary in case of respiratory failure 80 . Gastrostomy may be necessary to guarantee sufficient intake of calories and liquids 80 . Patients with sensorineural hearing loss will benefit from implantation of a cochlear device 80 patients with the isolated hepatic form of MDS due to DGUOKmutations 35 , MPV17-mutations 63, 67 , or in patients with hepatocerebral MDS. However, transplantation is controversial in the hepato-cerebral form if encephalopathy is a strong phenotypic component. Allogeneic hematopoetic stem cell transplantation is a promising therapeutic option in MNGIE 72 .
CONCLUSIONS
Mitochondrial depletion syndromes most frequently occur in neonates, infants, or juveniles, but rarely in adolescents or adults. Mutated genes phenotypically presenting with adult-onset MDS include POLG1, TK2, TyMP, RRM2B, and PEO1. In adults, MDS manifest either, like early-onset MDS, as myopathy, encephalo-myopathy, or hepato-cerebral syndrome, or with a phenotype at variance from that of the early-onset form. In adults, MDS also manifests with only minimal muscular manifestations. If histological examination of the muscle is normal but biochemical investigations reveal multiple RCC defects, particularly sparing complex II, MDS should be suspected and appropriate genes analysed for mutations in genes associated with MDS. From the few reported adult cases it can be concluded that the outcome appears to be more favorable than in the early-onset forms.
